Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Active, Not Recruiting

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

NCT03383094

Conditions
Cancer, Cancer of Head and Neck, Cancer, Advanced, +35 more
Locations
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • H. Lee Moffitt Cancer Center & Research Facility Tampa, Florida, United States
  • Washington University School of Medicine, Siteman Cancer Center St Louis, Missouri, United States
View Trial Details
Active, Not Recruiting

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

NCT05608044

Conditions
Colonic Diseases, Colorectal Neoplasms, Diabetes Mellitus, Insulin-Dependent, 12, +11 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Keck School of Medicine of the University of Southern California Los Angeles, California, United States
  • Rocky Mountain Cancer Center - Aurora Aurora, Colorado, United States
View all 65 locations
View Trial Details
Active, Not Recruiting

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

NCT04956692

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • St. Bernards Medical Center ( Site 0103) Jonesboro, Arkansas, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 0102) Fullerton, California, United States
  • Cancer Blood and Specialty Clinic ( Site 0105) Los Alamitos, California, United States
  • PIH Health Hematology Medical Oncology ( Site 0106) Whittier, California, United States
View all 126 locations
View Trial Details
Active, Not Recruiting

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • University of Arizona Cancer Center ( Site 0121) Tucson, Arizona, United States
  • UCSD Moores Cancer Center ( Site 0133) La Jolla, California, United States
  • The Angeles Clinic and Research Institute ( Site 0029) Los Angeles, California, United States
  • UCLA Hematology & Oncology ( Site 0130) Los Angeles, California, United States
View all 159 locations
View Trial Details
Active, Not Recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

NCT05382325

Conditions
Advanced or Metastatic Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Sanford Cancer Center ( Site 0005) Sioux Falls, South Dakota, United States
  • NEXT Oncology ( Site 0001) San Antonio, Texas, United States
  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011) Toronto, Ontario, Canada
  • Rambam Health Care Campus-Oncology ( Site 0021) Haifa, Israel
View Trial Details

Related conditions